Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy

Published: Thursday, August 21, 2014
Last Updated: Wednesday, August 20, 2014
Bookmark and Share
A predictive marker discovered by scientists at A*STAR and NUS could help doctors classify breast cancer patients for more effective treatment.

Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of a unique gene. The newly found marker could help doctors classify each breast cancer patient and customize a treatment regimen that is more effective.

The discovery was a collaborative effort by scientists from A*STAR's Institute of Molecular and Cell Biology (IMCB), and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).

Despite advancements in cancer treatment, breast cancer remains the most common cancer among Singapore women. Thirty percent of early breast cancer patients in the world experience relapse due to metastasis, or the spread of cancer cells to other organs in the body. Some patients also do not respond well to chemotherapy.

The inability to forecast relapses or the effectiveness of chemotherapy has led to a pressing need to identify predictive markers, which doctors can use to tailor appropriate treatment for each breast cancer patient at an early stage.

In a study published recently in the Journal of Clinical Investigation, a top-tier journal for discoveries in basic and clinical biomedical research, the team of scientists jointly led by Dr Vinay Tergaonkar, Principal Investigator at IMCB and Dr Alan Prem Kumar, Principal Associate at CSI Singapore and Assistant Professor at the Department of Pharmacology, NUS Yong Loo Lin School of Medicine, uncovered a gene, DP103, which is activated in metastatic breast cancer.

DP103 acts as a master regulator, which expresses two sets of unfavourable proteins - one leads to metastasis and the other causes patients to be unresponsive to chemotherapy. Consequently, doctors can predict the probability of metastasis by examining the levels of DP103 in breast cancer patients. The same gene could also be used to predict whether a patient would respond to chemotherapy.

"Doctors are unable to tell if a breast cancer patient will respond to chemotherapy until six months after the treatment has been prescribed. It is very worrisome as the ones who are not responsive to chemotherapy usually also suffer relapses due to metastasis. This DP103 gene that we found explains the link and will facilitate doctors in selecting suitable treatments for different cases of breast cancer," said Dr Tergaonkar.

In addition, the study revealed that reducing the levels of DP103 could contain the cancer, shrink the tumour and make patients more amenable to chemotherapy. All the findings in the study have been validated with samples of breast cancer patients from Singapore, Canada, China and the USA.

"DP103 is a novel biomarker that could help doctors select appropriate treatments for breast cancer patients at an early stage. It is also a therapeutic target which could be explored further to develop drugs that suppress breast cancer growth, as well as metastasis," said Dr Kumar, who first discovered DP103's oncogene potential to drive breast cancer metastasis. He is also the Principal Inventor to a patent application on this discovery and is currently looking into ways to regulate DP103 levels in a variety of cancer types at CSI Singapore.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A*STAR Findings on Breast Cancer Hold Potential for New Treatments
Computational techniques to increase understanding of diseases and improve patient treatments.
Friday, October 30, 2015
Gene Associated with an Aggressive Breast Cancer Identified
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment.
Wednesday, December 03, 2014
New Tool to Study Critical Protein Interaction in Cancer Research
A*STAR scientists used fluorescent molecular rotors to study protein-protein interactions involving p53 and MDM2 in cells.
Thursday, July 03, 2014
New Possibilities for Leukaemia Therapy with a Novel Mode of Cancer Cell Recognition
A new class of lipids in human leukaemia cells trigger an immune response to kill the cells.
Thursday, June 26, 2014
Singapore Scientists Discover New RNA Processing Pathway Important in hESCs
Discovery of RNA regulator could lead to a better understanding of diseases like cancer and influenza.
Monday, September 09, 2013
Scientists at GIS Discover Gene that Controls the Birth of Neurons
Discovery of long non-coding RNA's role in neurogenesis may lead to cures for diseases such as Alzheimer's disease.
Thursday, August 29, 2013
A*STAR Scientist Alex Matter Awarded Prestigious Szent-Gyorgyi Prize For Progress In Cancer Research
National Foundation for Cancer Research honours Professor Alex Matter with esteemed award for groundbreaking cancer pill that gives leukaemia patients a new lease of life.
Friday, April 05, 2013
A*STAR's GIS Collaborates with GSK to Further Research on Lung Cancer
Partnership will advance both organizations' joint efforts towards finding a cure for the disease.
Thursday, January 31, 2013
A*STAR Scientists Discover Potential Drug for Deadly Brain Cancer
This discovery can potentially prevent the progression and relapse of deadly brain tumours.
Tuesday, January 15, 2013
Singapore Scientists Identify New Biomarker for Cancer in Bone Marrow
This discovery may potentially cure patients of multiple myeloma.
Friday, December 14, 2012
A*STAR Scientists Identify Potential Drug Target for Inflammatory Diseases Including Cancers
This discovery holds the potential to reduce healthcare costs for many common inflammatory diseases such as cancer and diabetes.
Thursday, November 22, 2012
A*STAR Scientists Pinpoint Genetic Changes that Spell Cancer
Fruit flies light the way for scientists to uncover genetic changes.
Thursday, August 16, 2012
A*STAR Chief Scientist Wins Cancer Research UK Lifetime Achievement Prize
Professor Lane will receive the award at the National Cancer Research Institute Cancer Conference in Liverpool.
Thursday, July 19, 2012
Discovery of the Cellular Origin of Cervical Cancer
A team of scientists have identified a unique set of cells in the cervix that are the cause of HPV related cervical cancers.
Tuesday, June 12, 2012
A*STAR and GE Global Research Sign Memorandum of Understanding
Agreement to develop integrated advanced medical imaging technologies for improved clinical diagnosis.
Friday, April 13, 2012
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos